Core Insights - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is recognized as one of the 7 cheap pharmaceutical stocks to buy according to hedge funds [1] - JP Morgan has raised the price target for AMRX by $4 while maintaining a Buy rating [2] - The company has been added to the S&P SmallCap 600 Index, which is expected to enhance its visibility to investors and improve trading liquidity [3][8] Company Developments - Amneal Pharmaceuticals focuses on developing, manufacturing, and marketing generic and specialty branded medicines across various therapeutic areas, emphasizing cost-effective access and innovation [5] - A research collaboration and option agreement was established with KeifeRx to develop KFRX06, a preclinical candidate targeting LRRK2, which is associated with Parkinson's disease [4]

Core Viewpoint - KeifeRx has entered into a research collaboration and option agreement with Amneal Pharmaceuticals to advance the pre-IND development of KFRX06, a candidate targeting LRRK2 for Parkinson's disease [1] Company Summary - KeifeRx is a privately held biotechnology company focused on developing disease-modifying therapies for neurodegenerative disorders [1] - KFRX06 is a preclinical candidate aimed at inhibiting the LRRK2 gene, which is significantly associated with Parkinson's disease [1] Industry Summary - The collaboration with Amneal Pharmaceuticals is intended to support the pre-IND development phase, indicating a strategic partnership to enhance research capabilities in the neurodegenerative disorder space [1]